Analyze Portfolio
Nasdaq · Healthcare

DarioHealth Corp. (DRIO)

As-reported financials and recent SEC filings for DarioHealth Corp., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue
$22.4M
Net income
$-41.7M
Net margin
Diluted EPS
$10.12
ROE
-61.4%
P/E (TTM)
Market cap
Debt / equity
0.5×

Income statement (as reported)

LineFY2025FY2024FY2023FY2022FY2021
Revenue$22.4M$27.0M$20.4M$27.7M$20.5M
Gross profit$12.7M$13.3M$6.0M$9.7M$4.0M
Operating income$-36.7M$-57.7M$-56.2M$-56.8M$-76.5M
Net income$-41.7M$-42.7M$-59.4M$-62.2M$-76.8M
Diluted EPS$10.12$12.27$23.16$30.48$48.84

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

10-Q2026-05-13
View on EDGAR →
SD2026-05-07
View on EDGAR →
8-K2026-04-13
View on EDGAR →
8-K2026-03-30
View on EDGAR →
424B52026-03-30
View on EDGAR →
EFFECT2026-03-27
View on EDGAR →
CORRESP2026-03-25
View on EDGAR →

Largest Healthcare peers

All Healthcare companies →

Go deeper on DRIO

Search DarioHealth Corp.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.